Kodiak Sciences Inc.

KODSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1468748

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$267.6M	$217.3M	$107.4M	$37.5M	$18.8M
Operating Expenses	$341.4M	$267.1M	$136.0M	$49.2M	$26.4M
Operating Income (Loss)	-$341.4M	-$267.1M	-$136.0M	-$49.2M	-$26.4M
Interest Expense	$18.0K	$47.0K	$25.0K	$8.0K	$5.5M
Other Nonoperating Income (Expense)	$503.0K	-$190.0K	-$30.0K	$265.0K	-$4.7M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$333.8M	-$266.9M	-$133.1M	-$47.4M	-$41.4M
Income Tax Expense (Benefit)	$33.0K	$74.0K	$14.0K	$14.0K	$14.0K
Net Income (Loss) Attributable to Parent	-$333.8M	-$267.0M	-$133.1M	-$47.4M	-$41.4M
Earnings Per Share, Basic	-$6.39	-$5.16	-$2.91	—	—
Earnings Per Share, Diluted	-$6.39	-$5.16	-$2.91	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$479.4M	$666.6M	$904.2M	$1.1B	$358.9M
Assets, Current	$289.3M	$486.0M	$734.8M	$972.0M	$339.2M
Cash and Cash Equivalents, at Carrying Value	$190.4M	$731.5M	$944.4M	$211.8M	$88.3M
Liabilities	$213.6M	$230.5M	$240.9M	$206.6M	$13.5M
Liabilities, Current	$41.7M	$52.5M	$64.7M	$31.4M	$11.7M
Accounts Payable, Current	$13.6M	$9.1M	$12.4M	$8.6M	$2.6M
Stockholders' Equity Attributable to Parent	$663.3M	$860.8M	$345.4M	$86.8M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$206.5M	-$182.3M	-$83.4M	-$39.1M	-$29.0M
Net Cash Provided by (Used in) Investing Activities	-$336.5M	-$38.8M	$104.8M	-$137.0M	-$581.0K
Net Cash Provided by (Used in) Financing Activities	$1.9M	$8.2M	$717.4M	$299.7M	$116.5M
Payments to Acquire Property, Plant, and Equipment	$37.0M	$17.0M	$3.8M	$437.0K	$78.0K
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)